Turning Point Therapeutics, Inc.: directors' dealings · United States · SEC (Form 4)

About Turning Point Therapeutics, Inc.

Turning Point Therapeutics, Inc. was a U.S. precision-oncology biopharmaceutical company headquartered in San Diego, California, United States. The company was organized in October 2013 and began operations in 2014. It was originally a public-market biotech story associated with the U.S. NASDAQ before being acquired, and its historical profile is that of a classic clinical-stage oncology platform: high R&D intensity, meaningful binary clinical and regulatory risk, and significant upside optionality if lead assets demonstrate differentiation. For French, Belgian and Swiss investors, Turning Point is best understood as a specialist U.S. cancer-drug developer rather than a diversified pharmaceutical group. The company’s core business was the discovery and development of next-generation small-molecule targeted oncology therapies designed to address genetic drivers of cancer. Its scientific model combined tumor biology with structure-based drug design to create orally available proprietary candidates. The lead asset was repotrectinib, an investigational targeted therapy developed for tumors driven by ROS1 and NTRK alterations. That focus placed Turning Point in a high-value niche of precision medicine, where the addressable market is concentrated but where clinical differentiation can be highly rewarded if a molecule shows strong activity, tolerability, and resistance coverage. In competitive terms, Turning Point operated in one of the most crowded and scientifically demanding areas of oncology: targeted therapies for actionable mutations in solid tumors. Its differentiation strategy centered on creating a more advanced next-generation profile versus earlier-generation tyrosine kinase inhibitors, especially in ROS1-positive non-small cell lung cancer and other genomically defined cancers. The company’s operating footprint was primarily in the United States, and its SEC reporting described it as a single-segment business with headquarters in San Diego. A major milestone came when the U.S. FDA approved repotrectinib on November 15, 2023 for ROS1-positive non-small cell lung cancer, including patients previously treated with a ROS1 TKI. The FDA based the approval on the TRIDENT-1 study. Subsequently, Turning Point ceased to exist as an independent listed company after its acquisition by Bristol Myers Squibb, and repotrectinib is now marketed as AUGTYRO. For investors, the company exemplifies how a U.S.-listed oncology biotech can move from early clinical development to a strategic exit once a lead asset achieves regulatory validation and broader pharmaceutical commercial ownership.